E2F6 Antibody - BSA Free

Immunohistochemistry: E2F6 Antibody - BSA Free [NBP2-14936] -

The E2F6-CRNDE axis is clinically related to chemoresistant GC and poor outcome in advanced GC patients. (A) The expression of CRNDE and E2F6 were detected by qPCR assay in GC cell lines. (B) The correlation of CRNDE and E2F6 was analyzed in GC cell lines. (C) The subcellular localization and intensity of CRNDE were examined with in situ hybridization (ISH) in sections from GC patients. Scale bar: 50 um. (D) Retrospective analysis of Kaplan-Meier plots for CRNDE expression and the association with disease-free survival (DSF) and overall survival (OS) in GC patients. (E) Retrospective analysis of Kaplan-Meier plots for CRNDE expression and the association with disease-free survival (DSF) and overall survival (OS) in GC patients treated with oxaliplatin and 5-FU-based chemotherapy after surgery. (F) Representative ISH and IHC staining of GC tissues indicated a negative correlation between CRNDE and E2F6. Bars blow indicates the percentage of patients. Spearman's correlation analysis (G) Kaplan-Meier analysis of GC overall survival (OS) corresponding to the expression of E2F6 analysed by the online Kaplan Meier Plotter database (http://kmplot.com/analysis/). *P < 0.05, **P < 0.01, ***P < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36046639), licensed under a CC-BY license. Not internally tested by Novus Biologicals.